The effect of unfractionated heparin, enoxaparin, and danaparoid on lupus anticoagulant testing : can activated carbon eliminate false-positive results? by De Kesel, Pieter & Devreese, Katrien
Res Pract Thromb Haemost. 2019;00:1–8.	 	 	 | 	1wileyonlinelibrary.com/journal/rth2
 
Received:	21	July	2019  |  Revised:	12	September	2019  |  Accepted:	14	September	2019
DOI:	10.1002/rth2.12264		
B R I E F  R E P O R T
The effect of unfractionated heparin, enoxaparin, and 
danaparoid on lupus anticoagulant testing: Can activated 
carbon eliminate false‐positive results?
Pieter M.M. De Kesel  |   Katrien M.J. Devreese
This	is	an	open	access	article	under	the	terms	of	the	Creative	Commons	Attribution‐NonCommercial‐NoDerivs	License,	which	permits	use	and	distribution	in	
any	medium,	provided	the	original	work	is	properly	cited,	the	use	is	non‐commercial	and	no	modifications	or	adaptations	are	made.
©	2019	The	Authors.	Research and Practice in Thrombosis and Haemostasis	published	by	Wiley	Periodicals,	Inc	on	behalf	of	International	Society	on	Thrombosis	
and	Haemostasis.
Coagulation	Laboratory,	Department	of	
Laboratory	Medicine,	Ghent	University	
Hospital,	Ghent,	Belgium
Correspondence
Katrien	M.	J.	Devreese,	Coagulation	
Laboratory,	Department	of	Laboratory	
Medicine,	Ghent	University	Hospital,	
Corneel	Heymanslaan	10,	Ghent	9000,	
Belgium.
Email:	Katrien.Devreese@uzgent.be
Associate	Editor:	Pantep	Angchaisuksiri
Abstract
Background: Heparins	and	heparinoids	interfere	with	functional	clotting	assays	used	
for	lupus	anticoagulant	(LAC)	detection.	However,	current	guidelines	for	LAC	testing	
do	not	provide	clear	guidance	on	this	matter.
Objectives: We	aimed	to	assess	to	effect	of	unfractionated	heparin	(UFH),	enoxapa‐
rin,	and	danaparoid	on	LAC	assays	over	broad	anti‐Xa	activity	ranges	and	to	evaluate	
whether	activated	carbon	(AC)	is	able	to	neutralize	these	effects.
Methods: UFH	 (0.1‐3.0	 IU/mL),	 enoxaparin	 (0.2‐2.9	 IU/mL),	 and	 danaparoid	
(0.6‐2.2	IU/mL)	were	spiked	to	normal	pooled	plasma.	AC	was	added	at	multiple	ac‐
tivity	levels.	Anti‐Xa	assays	and	LAC	tests	were	performed	on	all	samples	using	Stago	
analyzers	and	reagents.
Results: Abnormal	activated	partial	thromboplastin	time	(APTT)	screening	and	mix‐
ing	 tests	 were	 obtained	 at	 the	 lowest	 levels	 for	 all	 compounds.	 Abnormal	 APTT	
confirmation	tests	were	seen	from	2.5	and	1.9	anti‐Xa	IU/mL	for	enoxaparin	and	da‐
naparoid,	respectively.	Abnormal	dilute	Russell’s	viper	venom	test	(dRVVT)	screening	
tests	were	obtained	from	1.6,	1.4,	and	1.1	anti‐Xa	IU/mL	for	UFH,	enoxaparin,	and	
danaparoid,	respectively.	Mixing	tests	were	abnormal	from	2.5	and	1.3	anti‐Xa	IU/mL	
for	enoxaparin	and	danaparoid,	respectively.	Abnormal	dRVVT	confirmation	results	
were	seen	for	danaparoid	only	from	1.9	anti‐Xa	IU/mL.	AC	was	unable	to	neutralize	
anti‐Xa	activity	in	plasma	and	overcome	the	effect	of	the	tested	anticoagulants	on	
LAC	assays	but	may	cause	prolongation	of	APTT	clotting	times.
Conclusions: UFH,	enoxaparin,	and	danaparoid	clearly	affected	LA	tests;	however,	
false‐positive	 LAC	 conclusions	were	obtained	 at	 supratherapeutic	 enoxaparin	 and	
danaparoid	levels	only.	AC	may	prolong	APTT	screen	clotting	times,	requiring	3‐step	
testing	to	avoid	potential	misdiagnosis	of	LAC.
K E Y W O R D S
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1  | INTRODUCTION
Detection	 of	 lupus	 anticoagulant	 (LAC),	 as	 part	 of	 the	 laboratory	
criteria	 for	 classification	 of	 antiphospholipid	 syndrome	 (APS),	 is	
performed	using	dilute	Russell’s	viper	venom	test	(dRVVT)	and	ac‐
tivated	partial	thromboplastin	time	(APTT),	being	phospholipid‐de‐
pendent	functional	clotting	assays.1‒3	Interference	of	anticoagulants	
is	a	well‐known	issue	in	LAC	testing	and	has	been	widely	addressed	
in	the	literature,	especially	for	vitamin	K	antagonists	(VKAs)	and	di‐
rect	oral	anticoagulants	(DOACs).4‒8	Unfractionated	heparin	(UFH),	
low‐molecular‐weight	heparins	(LMWHs),	and	heparinoids	also	carry	
the	intrinsic	potential	of	interfering	with	both	APTT	and	dRVVT,	as	
their	 anticoagulant	 activity	mainly	 originates	 from	 catalyzation	 of	
the	antithrombin‐mediated	inhibition	of	factors	IIa	and	Xa.9
Administration	of	LMWH	and	UFH	to	patients	with	APS	is	recom‐
mended	in	specific	cases	only,	for	example,	as	secondary	thrombo‐
prophylaxis	in	patients	with	APS	with	recurrent	venous	thrombosis	
treated	with	VKA,	 in	 pregnant	women	with	 a	 history	 of	 obstetric	
APS,	or	as	first‐line	treatment	in	catastrophic	APS.10	However,	pres‐
ence	of	heparins	 in	samples	admitted	to	the	clinical	 laboratory	for	
LAC	 testing	 is	 a	 common	 finding.8,11	The	 latter	 is	 often	 the	 result	
of	prompt	initiation	of	anticoagulant	therapy	after	clinical	diagnosis	
of	thromboembolism	and	subsequent	LAC	testing	as	part	of	throm‐
bophilia	screening.	This	carries	the	risk	of	physicians	or	 laboratory	
professionals	being	unaware	of	the	heparinized	state	of	the	patient	
when	interpreting	LAC	results,	especially	if	additional	tests,	such	as	
thrombin	 time	 or	 anti‐Xa	 activity	measurement,	 are	 not	 routinely	
performed.	The	ability	of	UFH	to	prolong	functional	clotting	assays	
and	thereby	cause	false‐positive	LAC	results	is	well	known.	On	the	
other	hand,	studies	investigating	the	effect	of	LMWH	on	LAC	detec‐
tion	showed	conflicting	results.	While	some	found	a	high	prevalence	
of	false‐positive	LAC	results	in	patients	treated	with	LMWH,7	others	
could	not	identify	such	an	effect	when	comparing	LMWH‐contain‐
ing	to	nonanticoagulated	samples.5
Current	 guidelines	 for	 laboratory	 detection	 of	 LAC	 issued	 by	
the	 International	Society	on	Thrombosis	and	Haemostasis	 (ISTH),2 
the	 Clinical	 and	 Laboratory	 Standards	 Institute,12	 and	 the	 British	
Committee	 for	 Standards	 in	 Haematology	 (BCSH)13 recommend 
caution	 when	 interpreting	 LAC	 tests	 in	 patients	 on	 heparins	 be‐
cause	 of	 the	 risk	 of	 false‐positive	 conclusions.	 The	 ISTH	 guide‐
line	 recommends	 performing	 LAC	 testing	 more	 than	 12	 hours	
after	 the	 last	 LMWH	 dose.	 The	 BCSH	 guideline	 states	 that	 LAC	
testing	 should	 not	 be	 performed	 in	 patients	 receiving	 therapeu‐
tic	doses	of	UFH,	while	prophylactic	UFH	or	LMWH	doses	should	
have	 less	 effect.	A	 recent	 survey	questionnaire	 performed	by	 the	
Scientific	and	Standardization	committee	for	Lupus	Anticoagulant/
Antiphospholipid	Antibodies	 of	 the	 ISTH	 showed	 that	 there	were	
a	variety	of	opinions	about	whether	and	when	to	 test	patients	on	
LMWH	or	UFH.14
For	 LAC	 detection	 in	 samples	 from	 patients	 on	 VKA	 treat‐
ment,	 the	 ISTH	 guideline	 provides	 International	 Normalized	
Ratio	 (INR)	 ranges	 at	 which	 LAC	 testing	 can	 still	 be	 performed	
(INR	<	1.5)	or	 could	be	done	after	mixing	 samples	1:1	with	nor‐
mal	pooled	plasma	(1.5	≤	INR	<3.0).	Similar	guidance,	for	instance,	
based	on	anti‐Xa	activity,	is	not	available	for	heparinized	samples.	
Therefore,	the	first	aim	of	this	study	was	to	assess	the	effect	of	
UFH,	 an	 LMWH	 (enoxaparin),	 and	 a	 heparinoid	 (danaparoid)	 on	
LAC	 assays	 over	 broad	 anti‐Xa	 activity	 ranges	 and	 to	 establish	
their	 potential	 for	 causing	 false‐positive	 results.	 In	 addition,	 it	
should	be	noted	that	many	commercial	reagents	used	for	LAC	de‐
tection	already	contain	 inhibitors	that	neutralize	heparin	effects	
up	to	specified	anti‐Xa	activity	levels.	Recently,	an	interesting	ap‐
proach	to	overcome	the	influence	of	DOAC	on	coagulation	assays	
has	been	introduced.	This	method,	DOAC‐Stop,	is	based	on	incu‐
bating	plasma	with	an	adsorbent	material,	consisting	of	activated	
carbon	(AC),	prior	to	further	testing.15	Several	studies	confirmed	
that	 this	approach	 is	able	 to	 remove	DOAC	from	plasma.16‒21 In 
this	 light,	 the	 second	aim	of	our	 study	was	 to	evaluate	whether	
AC	is	able	to	adsorb	heparins	and	heparinoids	and	neutralize	their	
effect	on	LAC	assays.
2  | MATERIALS AND METHODS
2.1 | Spiking experiment
Citrated	 whole	 blood	 (BD	 Vacutainer	 citrate	 3.2%,	 2.7	 mL;	 BD,	
Erembodegem,	 Belgium)	 was	 collected	 from	 15	 healthy	 volun‐
teers	 after	 informed	 consent.	 Normal	 pooled	 plasma	 (NPP)	 was	
obtained	 following	 double	 centrifugation	 at	 2230	 g	 for	 15	min‐
utes,	 stored	at	−80°C	and	 thawed	at	37°C	 for	5	minutes	before	
analysis.	 UFH	 (Heparine	 Leo	 100	 IU/mL	 solution	 for	 injection)	
was	purchased	 from	LEO	Pharma	 (Ballerup,	Denmark),	 enoxapa‐
rin	(Clexane	2000	IU	[20	mg]/0.2	mL	solution	for	 injection)	from	
Sanofi	(Diegem,	Belgium),	and	danaparoid	(Orgaran	750	IU/0.6	mL	
solution	 for	 injection)	 from	 Aspen	 Pharma	 (Dublin,	 Ireland).	
Starting	from	these	solutions,	working	solutions	at	20	anti‐Xa	IU/
mL	were	prepared	in	demineralized	water	for	all	3	anticoagulants	
and	added	to	NPP	to	obtain	broad	anti‐Xa	activity	ranges.	Anti‐Xa	
activity	measurement	and	LAC	testing	was	performed	in	neat	and	
spiked	NPP	as	described	below.
Essentials
∙	Heparins/heparinoids	may	interfere	with	laboratory	tests	for	lupus	anticoagulant	(LAC)	detection.
∙		We	evaluated	effects	of	unfractionated	heparin,	enoxaparin,	and	danaparoid	on	LAC	assays.
∙	False‐positive	LAC	conclusions	were	obtained	at	supratherapeutic	enoxaparin	and	danaparoid	levels.
∙	Activated	carbon	was	unable	to	eliminate	the	effects	but	prolonged	the	activated	partial	thromboplastin	time	clotting	times.
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2.2 | LAC testing and interpretation
According	 to	 current	 ISTH	 guidelines,2	 3‐step	 LAC	 testing	 was	
carried	 out	 in	 a	 dRVVT‐based	 and	 an	 APTT‐based	 test	 system.	
All	 tests	were	 carried	out	on	a	STA‐R	Evolution	analyzer	 (Stago,	
Asnières,	France).	Lupus	anticoagulant–sensitive	partial	thrombo‐
plastin	time	(PTT‐LA)	and	STA‐Staclot	dRVV	Screen	reagents	with	
low	phospolipid	content	 (both	Stago)	were	used	for	LAC	screen‐
ing	tests.	Mixing	tests	were	performed	on	patient	plasma	diluted	
1:1	with	NPP,	prepared	 in‐house	by	mixing	citrated	plasma	 from	
75	healthy	volunteers,	using	screen	reagents.	APTT	confirmation	
tests	were	carried	out	using	hexagonal	phase	phosphatidylethan‐
olamine	 (HPE)	 (Staclot	 LA,	 Stago)	 and	differences	between	 clot‐
ting	 times	measured	 in	 the	 absence	 and	 presence	 of	 HPE	were	
calculated.	For	dRVVT	confirmation	tests,	phospholipid‐rich	STA‐
Staclot	 DRVV	 Confirm	 reagent	 (Stago)	 was	 used.	 Mixing	 tests	
were	 also	 performed	 using	 this	 reagent.	 dRVVT	 screen/confirm	
ratios	were	used	as	confirmation	tests.	When	dRVVT	confirm	re‐
sults	exceeded	the	local	cutoff	values,	screen	mix/confirm	mix	ra‐
tios	were	applied.4	Analysis	of	NPP	in	each	sample	batch	allowed	
normalization	of	clotting	times	and	calculation	of	normalized	clot‐
ting	 time	 ratios	 (NCRs)	 for	 screening,	 mixing,	 and	 confirmation	
assays.	 For	 individual	 test	 interpretation,	 NCRs	 were	 compared	
with	 local	 cutoffs	 calculated	 as	99th	percentiles	on	120	healthy	
donors.2,22,23	Cutoff	values,	expressed	as	NCRs	except	for	Staclot	
LA,	were	1.48	for	dRVV	screen,	1.19	for	dRVV	screen	mix,	1.21	for	
dRVV	confirm,	1.10	for	dRVV	confirm	mix,	1.21	for	dRVV	screen/
confirm	 ratio,	 1.10	 for	 dRVV	 screen	mix/confirm	mix	 ratio,	 1.35	
for	PTT‐LA	screen,	1.13	for	PTT‐LA	screen	mix,	and	8.00	seconds	
for	 Staclot	 LA.	 For	 the	 dRVVT	 system,	mixing	 and	 confirmation	
tests	were	performed	simultaneously	 if	NCRs	of	 screening	 tests	
exceeded	 cutoffs.	 For	 the	 APTT	 system,	mixing	 tests	were	 per‐
formed	first	when	screening	tests	were	prolonged.	Confirmation	
testing	 was	 performed	 only	 if	 both	 screening	 and	 mixing	 tests	
exceeded	cutoffs,	as	 this	 is	a	partly	manual	procedure.	LAC	was	
considered	positive	if	screening,	mixing,	and	confirmation	steps	all	
exceeded	cutoff	values	in	at	least	1	of	both	test	systems.
2.3 | Anti‐Xa activity measurement
Anti‐Xa	activity	was	measured	using	calibrated,	chromogenic	anti‐Xa	
assays	 (STA‐Liquid	 anti‐Xa,	 Stago).	 For	 UFH	 and	 enoxaparin,	 STA‐
Multi	Hep	Calibrator	plasma	(Stago)	was	used.	Biophen	Orgaran	cali‐
bration	plasma	(Hyphen	BioMed,	Neuville‐sur‐Oise,	France)	was	used	
for	danaparoid.	All	analyses	were	performed	on	STA	analyzers	(Stago).
2.4 | Sample pretreatment with AC
Norit	 Carbomix	 (Norit	 Pharmaceuticals,	 Klazienaveen,	 The	
Netherlands),	an	AC	granulate	intended	for	suspension	in	water	and	
subsequent	oral	administration	as	reversal	agent	 in	acute	 intoxica‐
tions,	was	used.	This	AC	formulation	allows	homogenous	and	rapid	
suspension	of	AC	in	plasma	samples.	To	determine	the	optimal	AC	
concentration,	 increasing	 concentrations	 (0,	 40,	 80,	 and	 120	mg/
mL)	were	added	to	NPP	spiked	with	UFH	(1.4	anti‐Xa	IU/mL),	enoxa‐
parin	(1.5	anti‐Xa	IU/mL),	and	danaparoid	(1.3	anti‐Xa	IU/mL).	After	
addition	of	AC,	samples	were	mixed	for	5	minutes	and	centrifuged	
for	15	minutes	at	2230	g.	The	supernatant	was	collected	for	further	
analysis.	Anti‐Xa	activities	were	measured	in	all	samples.
An	AC	concentration	of	40	mg/mL	was	selected	for	further	ex‐
periments.	At	multiple	anti‐Xa	activity	levels,	aliquots	of	spiked	NPP	
were	pretreated	with	40	mg/mL	AC.	Anti‐Xa	activity	measurement,	
and	LAC	testing	was	performed	on	AC‐treated	and	untreated	plasmas.
3  | RESULTS AND DISCUSSION
3.1 | In vitro effect of UFH, enoxaparin, and 
danaparoid on lupus anticoagulant assays
3.1.1 | General findings
For	UFH	and	enoxaparin,	12‐point	anti‐Xa	activity	levels	ranged	from	
0.1	to	3.0	IU/mL	and	from	0.2	to	2.9	IU/mL,	respectively.	Six‐point	
anti‐Xa	activity	levels	for	danaparoid	ranged	from	0.6	to	2.2	IU/mL.	
These	broad	activity	ranges	allowed	to	evaluate	the	 impact	of	 the	
tested	anticoagulants	on	LAC	assays	from	sub‐	to	supratherapeutic	
levels.9,24,25	In	Figure	1,	dRVVT	and	APTT	screening,	mixing	and	con‐
firmation	results	are	depicted	in	function	of	measured	anti‐Xa	activ‐
ity	in	NPP	spiked	with	UFH,	enoxaparin,	and	danaparoid.	It	is	clear	
that	 all	 3	 anticoagulants	 prolong	 both	 APTT	 and	 dRVVT	 results,	
with	APTT	being	affected	most.	UFH	exerted	the	highest	effect	on	
both	assays,	while	the	influence	of	enoxaparin	and	danaparoid	was	
comparable.	These	general	findings	are	in	agreement	with	previous	
observations.5,7	Anti‐Xa	activity	levels	at	which	LAC	test	results	ex‐
ceeded	the	local	cutoffs	are	summarized	in	Table	1.
3.1.2 | APTT test system
Abnormal	 APTT	 screening	 and	 mixing	 results	 were	 obtained	 at	
the	lowest	anti‐Xa	activity	levels	(0.1,	0.2,	and	0.6	anti‐Xa	IU/mL	
for	UFH,	enoxaparin,	 and	danaparoid,	 respectively).	 It	 should	be	
noted	that	the	PTT‐LA	screen	reagent	used	in	these	assays	does	
not	contain	a	heparin‐neutralizing	agent,	which	results,	for	exam‐
ple,	 in	 screening	 results	 outside	 the	 measurement	 range	 of	 the	
assay	 starting	 from	1.0	 anti‐Xa	 IU/mL	UFH.	The	 Staclot	 LA	 rea‐
gent	used	 for	APTT	confirmation	 testing	does	contain	a	heparin	
inhibitor,	with	the	manufacturer	stating	that	heparin	 levels	up	to	
1.0	anti‐Xa	IU/mL	do	not	interfere	with	the	assay.	Indeed,	abnor‐
mal	 results	were	 obtained	 at	 high	 enoxaparin	 (starting	 from	2.5	
anti‐Xa	 IU/mL)	 and	danaparoid	 (starting	 from	1.9	 anti‐Xa	 IU/mL)	
levels.	 Interestingly,	 prolongation	 of	 Staclot	 LA	 clotting	 times	
by	 UFH	 seems	 to	 be	 phospholipid	 dependent	 as	 high	 UFH	 lev‐
els	 (starting	 from	1.6	 anti‐Xa	 IU/mL)	prolonged	 clotting	 times	 in	
the	 presence	 of	 hexagonal	 phase	 phospholipids	 to	 a	 higher	 ex‐
tent	than	clotting	times	in	the	absence	of	phospholipids.	This	re‐
sulted	 in	APTT	 confirmation	 results	 never	 exceeding	 the	 cutoff.	
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F I G U R E  1  Dilute	Russell’s	viper	
venom	test	(dRVVT)‐	and	activated	partial	
thromboplastin	time	(APTT)‐based	lupus	
anticoagulant	screening,	mixing	and	
confirmation	clotting	times	in	function	
of	measured	anti‐Xa	activity	(IU/mL)	
in	normal	pooled	plasma	spiked	with	
unfractionated	heparin	(UFH),	enoxaparin,	
and	danaparoid.	Red	dotted	lines	indicate	
in‐house	cutoff	values
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Danaparoid (anti-Xa IU/mL)
0.0 0.6 0.8 1.1 1.3 1.9 2.2
Danaparoid (anti-Xa IU/mL)
0.0 0.6 0.8 1.1 1.3 1.9 2.2
Danaparoid (anti-Xa IU/mL)
0.0 0.6 0.8 1.1 1.3 1.9 2.2
Danaparoid (anti-Xa IU/mL)
0.0 0.6 0.8 1.1 1.3 1.9 2.2
Danaparoid (anti-Xa IU/mL)
0.0 0.6 0.8 1.1 1.3 1.9 2.2
Danaparoid (anti-Xa IU/mL)
0.0 0.6 0.8 1.1 1.3 1.9 2.2
Danaparoid (anti-Xa IU/mL)
0.0 0.6 0.8 1.1 1.3 1.9 2.2
Enoxaparin (anti-Xa IU/mL)
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.3 1.4 1.6 2.1 2.5 2.9
Enoxaparin (anti-Xa IU/mL)
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.3 1.4 1.6 2.1 2.5 2.9
Enoxaparin (anti-Xa IU/mL)
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.3 1.4 1.6 2.1 2.5 2.9
Enoxaparin (anti-Xa IU/mL)
0.0 0.2 0.4 0.6 0.8 1.0 1.2 1.3 1.4 1.6 2.1 2.5 2.9
0.0 0.1 0.4 0.5 0.8 1.0 1.3
UFH (anti-Xa IU/mL)
1.5 1.6 1.9 2.0 2.5 3.0
0.0 0.1 0.4 0.5 0.8 1.0 1.3
UFH (anti-Xa IU/mL)
1.5 1.6 1.9 2.0 2.5 3.0
0.0 0.1 0.4 0.5 0.8 1.0 1.3
UFH (anti-Xa IU/mL)
1.5 1.6 1.9 2.0 2.5 3.0
0.0 0.1 0.4 0.5 0.8 1.0 1.3
UFH (anti-Xa IU/mL)
1.5 1.6 1.9 2.0 2.5 3.0
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Altogether,	false‐positive	LAC	conclusions	in	the	APTT‐based	test	
system	were	obtained	at	supratherapeutic	enoxaparin	and	danap‐
aroid	levels,	starting	from	2.5	and	1.9	anti‐Xa	IU/mL,	respectively.
3.1.3 | dRVVT test system
As	previously	mentioned,	dRVVT	assays	were	 less	 impacted	com‐
pared	 to	 APTT‐based	 tests.	 According	 to	 the	 manufacturer,	 a	
heparin‐neutralizing	agent	is	contained	in	dRVV	reagents,	quenching	
heparin	up	to	0.8	anti‐Xa	IU/mL.	For	UFH	and	enoxaparin,	dRVVT	
screen	NCRs	started	to	prolong	at	anti‐Xa	activity	levels	higher	than	
the	level	stated	by	the	manufacturer,	with	abnormal	results	obtained	
from	 1.6	 IU/mL	 and	 1.4	 IU/mL	 anti‐Xa	 activity	 on,	 respectively.	
dRVVT	screen	NCRs	in	danaparoid‐spiked	samples	prolonged	from	
0.8	anti‐Xa	IU/mL	on	and	exceeded	the	cutoff	from	1.1	anti‐Xa	IU/
mL	on.	For	UFH,	mixing	test	results	using	the	screen	reagent	never	
exceeded	the	cutoff.	For	enoxaparin	and	danaparoid,	abnormal	mix‐
ing	 tests	were	 obtained	 starting	 from	 2.5	 and	 1.3	 anti‐Xa	 IU/mL,	
respectively.	Although	prolongation	of	mixing	tests	was	minimal	in	
the	latter	2	cases,	results	above	the	cutoff	values	were	considered	
relevant	as	they	exceeded	the	analytical	variability	of	the	assay.	For	
dRVVT	confirmation	testing,	screen	mix/confirm	mix	ratios	were	ap‐
plied	as	confirm	clotting	times	were	clearly	prolonged	at	the	anti‐Xa	
activity	levels	where	screen	clotting	times	were	prolonged	as	well.	
The	effects	of	UFH	and	enoxaparin	on	dRVVT	tests	seem	to	be	in‐
dependent	from	phospholipid	content,	as	screen	and	confirm	results	
were	affected	to	a	similar	extent.	This	resulted	 in	screen	mix/con‐
firm	mix	ratios	never	exceeding	the	cutoff.	For	danaparoid,	abnor‐
mal	ratios	were	seen	from	1.9	anti‐Xa	IU/mL,	although	differences	
between	obtained	NCRs	and	cutoff	values	were	within	the	assay’s	
analytical	variability	and,	therefore,	seem	to	be	less	relevant.
3.1.4 | Summary
UFH,	 enoxaparin,	 and	 danaparoid	 clearly	 affected	 LAC	 assays,	
especially	 APTT‐based	 tests,	 with	 abnormal	 screening	 and	 mix‐
ing	 tests	 in	 this	 test	 system	already	 seen	 at	 low	anti‐Xa	 activity	
levels.	However,	applying	 the	3‐step	procedure	 including	 results	
of	 confirmation	 tests,	 UFH	 did	 not	 result	 in	 false‐positive	 LAC,	
while	 enoxaparin	 as	 well	 as	 danaparoid	 caused	 false‐positive	
TA B L E  1  Anti‐Xa	activity	levels	in	normal	pooled	plasma	spiked	
with	unfractionated	heparin,	enoxaparin,	and	danaparoid	at	which	
lupus	anticoagulant	tests,	performed	using	dilute	Russell's	viper	
venom	test–	and	activated	partial	thromboplastin	time–based	
clotting	assays,	were	false	positive
 
UFH 
(anti‐Xa 
IU/mL)
Enoxaparin 
(anti‐Xa IU/mL)
Danaparoid 
(anti‐Xa IU/mL)
(A)	dRVVT	system
Screening ≥1.6 ≥1.4 ≥1.1
Mixing … ≥2.5 ≥1.3
Confirmation … … ≥1.9
Conclusion … … ≥1.9
(B)	APTT	system
Screening ≥0.1 ≥0.2 ≥0.6
Mixing ≥0.1 ≥0.2 ≥0.6
Confirmation … ≥2.5 ≥1.9
Conclusion … ≥2.5 ≥1.9
(C)	LAC	
conclusion
… ≥2.5 ≥1.9
Abbreviations:	APTT,	activated	partial	thromboplastin	time;	dRVVT,	
dilute	Russell’s	viper	venom	test;	LAC,	lupus	anticoagulant;	UFH,	un‐
fractionated	heparin.
 Anti‐Xa IU/mL
dRVVT screen (s) APTT screen(s)
Before AC After AC Before AC After AC
Neat	NPP … 32.5 31.5 35.6 35.3
UFH 0.1 41.1 40.4 64.5 78.3
0.4 43.7 42.1 109.8 140.5
0.8 44.0 44.6 245.2 298.0
1.3 43.0 43.7 >300.0 >300.0
2.0 204.1 254.1 >300.0 >300.0
Enoxaparin 0.2 39.3 43.7 47.8 49.6
0.4 38.6 39.6 54.8 59.8
0.8 43.1 39.8 74.2 79.2
1.2 48.0 43.4 93.9 101.1
2.1 62.0 67.9 145.1 191.5
Danaparoid 0.6 42.2 40.5 58.2 59.1
1.1 53.3 51.1 76.3 76.4
1.9 97.3 89.9 124.6 132.6
Abbreviations:	AC,	activated	carbon;	APTT,	activated	partial	thromboplastin	time;	dRVVT,	dilute	
Russell’s	viper	venom	test;	NPP,	normal	pooled	plasma;	UFH,	unfractionated	heparin.
TA B L E  2  Dilute	Russell’s	viper	
venom	test	screen	and	activated	partial	
thromboplastin	time	screen	clotting	times	
measured	in	neat	normal	pooled	plasma	
and	normal	pooled	plasma	spiked	with	
unfractionated	heparin,	enoxaparin,	and	
danaparoid	at	different	anti‐Xa	activity	
levels	before	and	after	incubation	of	
plasma	with	activated	carbon
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APTT‐based	LAC	conclusions	at	supratherapeutic	anti‐Xa	activity	
levels	starting	from	2.5	and	1.9	anti‐Xa	IU/mL,	respectively.9,24,25 
dRVVT	screening	and	mixing	tests	were	influenced	as	well,	albeit	at	
higher	anti‐Xa	activity	levels	compared	to	APTT.	Abnormal	dRVVT	
confirmation	tests	and,	consequently,	false‐positive	dRVVT‐based	
LAC	conclusions	were	observed	for	danaparoid	only,	at	high	anti‐
Xa	activity	levels	(from	1.9	anti‐Xa	IU/mL	on).	Anti‐Xa	activity	lev‐
els	 at	which	 false‐positive	 LAC	 results	were	 obtained	 exceeded	
those	mentioned	in	the	package	inserts	of	the	evaluated	reagents	
up	to	where	included	inhibitors	should	neutralize	heparin	effects.
3.2 | Impact of AC on anti‐Xa activity and LAC assays
3.2.1 | AC concentration
Initial	anti‐Xa	activities	in	untreated	spiked	NPP	were	1.4,	1.5,	and	
1.3	 anti‐Xa	 IU/mL	 for	UFH,	enoxaparin,	 and	danaparoid,	 respec‐
tively.	 Identical	 results	 were	 obtained	 for	 samples	 to	 which	 40	
and	80	mg/mL	AC	was	added.	When	120	mg/mL	AC	was	added,	
slightly	higher	anti‐Xa	activities	were	measured	(1.6,	1.7,	and	1.4	
anti‐Xa	IU/mL	for	UFH,	enoxaparin,	and	danaparoid,	respectively).	
The	 latter	 may	 be	 attributed	 to	 incomplete	 removal	 of	 high	 AC	
concentrations	after	 centrifugation	and	 subsequent	 interference	
with	the	chromogenic	anti‐Xa	assay	or	to	adsorption	of	water	by	
AC,	 resulting	 in	 increased	 anticoagulant	 plasma	 concentrations.	
As	there	was	no	benefit	from	using	higher	AC	concentrations,	the	
lowest	tested	concentration	(40	mg/mL)	was	selected	for	further	
experiments.	AC	concentrations	<40	mg/mL	were	not	tested,	as	it	
was	previously	described	by	others	that	lower	AC	concentrations,	
being	5	mg/mL26	and	20	mg/mL,27	are	unable	to	eliminate	the	ef‐
fect	 of	 heparins	 and	 heparinoids	 on	 routine	 clotting	 assays.	 As	
routine	clotting	tests	(APTT,	STA‐PTTA,	Stago;	prothrombin	time,	
STA‐NeoPTimal,	Stago;	thrombin	time,	STA‐Thrombin,	Stago;	data	
not	shown)	and	LAC	screening	 tests	 (PTT‐LA	screen	and	dRVVT	
screen,	Table	2)	performed	on	NPP	were	not	affected	by	40	mg/
mL	AC,	this	AC	concentration	could	be	used	safely.	By	using	the	
same	AC	product	as	in	our	study,	Frans	et	al27	also	showed	that	AC	
concentrations	up	to	80	mg/mL	did	not	significantly	interfere	with	
routine	clotting	assays	in	neat	plasma	from	healthy	volunteers.
3.2.2 | Anti‐Xa activity
Anti‐Xa	activity	values	for	UFH,	enoxaparin,	and	danaparoid	obtained	
before	and	after	incubating	spiked	NPP	with	AC	(40	mg/mL)	are	shown	
in	Figure	2.	Wilcoxon	signed‐rank	tests	revealed	no	significant	differ‐
ences	between	results	before	and	after	AC.	These	results	indicate	that	
AC	does	not	adsorb	the	3	tested	anticoagulants	from	plasma.	Similar	
findings	were	recently	described	by	Exner	et	al26	using	DOAC‐Stop.	
3.2.3 | LAC assays
Table	 2	 summarizes	 dRVVT	 screen	 and	 PTT‐LA	 screen	 clotting	
times	measured	in	neat	NPP	and	NPP	spiked	with	UFH,	enoxaparin,	
and	 danaparoid	 at	 different	 anti‐Xa	 activity	 levels.	 Although	 in‐
cubation	 of	 plasma	 with	 AC	 did	 not	 alter	 interpretation	 of	 LAC	
results,	 changes	 in	 APTT	 screen	 clotting	 times	 were	 noticed.	
Consistently	 longer	 clotting	 times	 after	 AC	 were	 seen	 in	 UFH‐	
and	enoxaparin‐spiked	samples.	Differences	ranged	from	13.8	to	
52.8	seconds	for	UFH	(mean	difference,	23.6	±	3.8%)	and	from	1.8	
to	46.4	 seconds	 for	enoxaparin	 (mean	difference,	13.1	±	18.7%).	
The	 more	 pronounced	 prolongation	 in	 UFH‐containing	 samples	
might	potentially	originate	from	the	adsorption	of	water	and	some	
enoxaparin	by	AC,	while	UFH	is	excluded	from	AC	due	to	its	higher	
molecular	size.	Prolongation	of	APTT	mixing	test	results	(using	the	
same	PTT‐LA	screen	reagent)	and	confirmation	tests	(using	Staclot	
F I G U R E  2  Anti‐Xa	activity	obtained	before	and	after	adding	
activated	carbon	(AC)	at	40	mg/mL	to	normal	pooled	plasma	spiked	
with	unfractionated	heparin	(UFH),	enoxaparin	and	danaparoid.	P 
values	result	from	Wilcoxon	signed‐rank	tests
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LA	 reagent	 containing	HPE)	was	noticed	as	well,	 but	differences	
were	limited	compared	to	screening	tests	(mean	differences	before	
and	 after	AC	 for	UFH	and	enoxaparin,	 respectively,	 14.8	±	6.9%	
and	3.2	±	2.4%	for	mixing	tests	and	6.4	±	6.4%	and	2.9	±	5.1%	for	
confirmation	tests).	It	should	be	noted	that	sample	sizes	are	small	
and	that	the	differences	observed	for	PTT‐LA	screen	were	statisti‐
cally	insignificant	based	on	Wilcoxon	signed‐rank	tests.	Moreover,	
these	 findings	obtained	using	1	 type	of	AC	and	1	APTT	 reagent	
probably	may	not	be	generalized	for	other	AC	products	or	APTT	
reagents.	Although	not	explicitly	mentioned	by	the	authors,	a	simi‐
lar	pattern	was	seen	in	the	study	by	Exner	et	al26	for	NPP	spiked	
with	 enoxaparin	 and	 treated	 with	 DOAC‐Stop.	 Prolongation	 of	
APTT	results	after	applying	DOAC‐Stop	was	previously	 reported	
as	well.15,16	Differences	between	APTT	results	for	danaparoid	and	
between	dRVVT	results	for	all	3	anticoagulants	were	 limited	and	
statistically	insignificant.
3.2.4 | Summary
AC	proved	unable	 to	neutralize	 anti‐Xa	 activity	of	UFH,	 enoxaparin,	
and	danaparoid	 in	plasma	and	overcome	their	effect	on	LAC	testing.	
Furthermore,	 incubating	 samples	 with	 the	 AC	 product	 used	 in	 this	
study	 may	 cause	 prolongation	 of	 APTT	 screening	 clotting	 times	 in	
UFH‐	and	enoxaparin‐containing	samples	starting	from	low	anti‐Xa	lev‐
els,	requiring	3‐step	LAC	testing	to	avoid	potential	misdiagnosis	of	LAC.
4  | CONCLUSIONS 
Applying	the	3‐step	procedure	for	LAC	testing,	including	a	screening,	
mixing,	and	confirmation	step,	avoids	misclassification	for	LAC	in	the	
APTT	test	system	caused	by	prolongation	of	APTT	by	UFH.	For	LMWH	
(enoxaparin)	 and	danaparoid,	 false‐positive	LAC	 results	 in	 the	APTT	
test	system	are	observed,	although	at	supratherapeutic	anti‐Xa	activ‐
ity	levels.	In	the	dRVVT	test	system,	only	false‐positive	LAC	results	for	
danaparoid	were	observed,	again	at	high	anti‐Xa	levels.	In	contrast	to	
DOACs,	heparins/heparinoids	are	not	adsorbed	by	AC,	and	thus	is	not	
suited	to	avoid	interference	of	heparin	therapy	in	LAC	testing.
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